Company: EDSA
Filing Date: 2025-10-28
Form Type: 8-K
Source: 0001171843-25-006690
Chunk: 2

Company: Edesa Biotech, Inc.
Filing Date: 2025-10-28
Form: 8-K
Item: Item 8.01
Chunk 2
---
�─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  0.38 (0.31, 0.45)                                                                                                                                                                                         0.27 (0.21, 0.33)          0.032  
  Adjusted risk estimate: variables included age, baseline WCSS, baseline antiviral use, baseline corticosteroid use, baseline immunomodulator use, concomitant antiviral use, concomitant corticos...                                        

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                              Edesa Biotech, Inc.                               
  Date: October 28, 2025      By:                      /s/ Peter J. Weiler      
                              Name:                    Peter J. Weiler          
                              Title:                   Chief Financial Officer